Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 10 No. 1, January 2009
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleck, B. W.
Right arrow Articles by McIntosh, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fleck, B. W.
Right arrow Articles by McIntosh, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

NeoReviews Vol.10 No.1 2009 e20
© 2009 American Academy of Pediatrics

Retinopathy of Prematurity

Recent Developments

Brian W. Fleck, MD, FRCS, FRCOph*
Neil McIntosh, DSc(Med), MRCP{dagger}

* Consultant Ophthalmologist, Department of Neonatology, Simpson's Centre for Reproductive Health, Royal Infirmary, Edinburgh, United Kingdom; Royal Hospital for Sick Children, Edinburgh, United Kingdom
{dagger} Emeritus Professor of Child Life and Health, University of Edinburgh; Department of Neonatology, Simpson's Centre for Reproductive Health, Royal Infirmary, Edinburgh, United Kingdom

Retinopathy of prematurity (ROP) is a disorder of retinal vascular development in preterm infants. It remains a major cause of childhood blindness worldwide. This review addresses advances in knowledge during the past 8 years. The pathogenesis has become clearer with animal experimental work and from clinical observations. Large clinical trials have informed better management, and new retinal digital imaging is likely to change the role of the ophthalmologist. New treatment modalities, such as vascular endothelial growth factor (VEGF)-blocking antibodies, are being assessed. Finally, a number of evidence-based clinical guidelines for the management of ROP have been published.

Abbreviations: AP-ROP: aggressive posterior ROP • BIO: binocular indirect ophthalmoscope • ETROP: Early Treatment of ROP • IGF-1: insulin-like growth factor-1 • ROP: retinopathy of prematurity • SGA: small for gestational age • VEGF: vascular endothelial growth factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Academy of Pediatrics.